Zacks Investment Research Downgrades Menlo Therapeutics (NASDAQ:MNLO) to Hold

Share on StockTwits

Zacks Investment Research cut shares of Menlo Therapeutics (NASDAQ:MNLO) from a buy rating to a hold rating in a research report released on Thursday morning, Zacks.com reports.

According to Zacks, “Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company’s product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California. “

Separately, Cantor Fitzgerald reiterated a buy rating and set a $25.00 price objective on shares of Menlo Therapeutics in a research note on Wednesday, February 27th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $17.00.

MNLO opened at $6.24 on Thursday. The company has a market cap of $149.36 million, a PE ratio of -2.63 and a beta of 2.98. Menlo Therapeutics has a 52-week low of $3.74 and a 52-week high of $12.00.

Menlo Therapeutics (NASDAQ:MNLO) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.81). As a group, sell-side analysts forecast that Menlo Therapeutics will post -3.37 EPS for the current fiscal year.

Several large investors have recently modified their holdings of MNLO. Rhumbline Advisers bought a new stake in shares of Menlo Therapeutics in the fourth quarter worth $48,000. Acadian Asset Management LLC bought a new stake in shares of Menlo Therapeutics in the fourth quarter worth $147,000. Bank of New York Mellon Corp increased its stake in shares of Menlo Therapeutics by 51.0% in the fourth quarter. Bank of New York Mellon Corp now owns 38,662 shares of the company’s stock worth $159,000 after buying an additional 13,064 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Menlo Therapeutics by 8.9% in the fourth quarter. Bank of America Corp DE now owns 42,160 shares of the company’s stock worth $173,000 after buying an additional 3,448 shares during the last quarter. Finally, TIAA CREF Investment Management LLC bought a new stake in shares of Menlo Therapeutics in the third quarter worth $184,000. Institutional investors and hedge funds own 73.95% of the company’s stock.

Menlo Therapeutics Company Profile

Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough.

Further Reading: What is the formula for calculating total return?

Get a free copy of the Zacks research report on Menlo Therapeutics (MNLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wells Fargo & Co  Given Consensus Rating of “Hold” by Brokerages
Wells Fargo & Co Given Consensus Rating of “Hold” by Brokerages
Nitro Achieves Market Cap of $291,188.00
Nitro Achieves Market Cap of $291,188.00
Ethouse Price Reaches $0.0020
Ethouse Price Reaches $0.0020
HBZ coin  Price Down 19.5% Over Last Week
HBZ coin Price Down 19.5% Over Last Week
Hercules  Price Down 7.5% Over Last Week
Hercules Price Down 7.5% Over Last Week
Zacks: Analysts Anticipate Aevi Genomic Medicine Inc  Will Post Earnings of -$0.10 Per Share
Zacks: Analysts Anticipate Aevi Genomic Medicine Inc Will Post Earnings of -$0.10 Per Share


 
© 2006-2019 Zolmax.